Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Average Recommendation of “Hold” by Brokerages

Posted by on May 6th, 2023

Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Rating) have received a consensus rating of “Hold” from the eleven analysts that are presently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, four have given a hold recommendation and four have given a buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $11.17.

Several analysts have commented on the company. Northland Securities lowered Esperion Therapeutics from a “market perform” rating to an “under perform” rating in a report on Thursday, March 16th. StockNews.com assumed coverage on Esperion Therapeutics in a research report on Thursday, March 16th. They set a “hold” rating for the company. Morgan Stanley raised Esperion Therapeutics from an “underweight” rating to an “equal weight” rating and set a $9.00 target price for the company in a research note on Friday, February 3rd. Bank of America cut Esperion Therapeutics from a “neutral” rating to an “underperform” rating and lowered their target price for the company from $8.00 to $1.50 in a report on Thursday, March 16th. Finally, JMP Securities restated a “market outperform” rating and set a $15.00 price objective on shares of Esperion Therapeutics in a report on Monday, March 6th.

Insiders Place Their Bets

In related news, insider Eric Warren sold 5,090 shares of the stock in a transaction that occurred on Tuesday, March 7th. The shares were sold at an average price of $5.05, for a total value of $25,704.50. Following the completion of the transaction, the insider now owns 48,572 shares of the company’s stock, valued at approximately $245,288.60. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Esperion Therapeutics news, insider Eric Warren sold 5,090 shares of the firm’s stock in a transaction on Tuesday, March 7th. The shares were sold at an average price of $5.05, for a total value of $25,704.50. Following the completion of the sale, the insider now directly owns 48,572 shares in the company, valued at $245,288.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Sheldon L. Koenig sold 5,441 shares of the firm’s stock in a transaction on Tuesday, March 7th. The shares were sold at an average price of $5.06, for a total transaction of $27,531.46. Following the completion of the transaction, the chief executive officer now directly owns 194,815 shares in the company, valued at $985,763.90. The disclosure for this sale can be found here. Insiders have sold a total of 22,743 shares of company stock worth $74,258 in the last quarter. Corporate insiders own 0.60% of the company’s stock.

Institutional Investors Weigh In On Esperion Therapeutics

Several hedge funds have recently bought and sold shares of ESPR. Braidwell LP purchased a new stake in shares of Esperion Therapeutics in the 4th quarter worth about $21,141,000. Wasatch Advisors Inc. raised its stake in Esperion Therapeutics by 27.6% during the 1st quarter. Wasatch Advisors Inc. now owns 8,147,380 shares of the biopharmaceutical company’s stock worth $37,804,000 after acquiring an additional 1,761,117 shares during the period. Millennium Management LLC grew its holdings in Esperion Therapeutics by 116.8% during the 2nd quarter. Millennium Management LLC now owns 2,706,290 shares of the biopharmaceutical company’s stock valued at $17,212,000 after buying an additional 1,457,952 shares in the last quarter. Two Sigma Advisers LP grew its holdings in Esperion Therapeutics by 7,991.8% during the 3rd quarter. Two Sigma Advisers LP now owns 1,084,300 shares of the biopharmaceutical company’s stock valued at $7,265,000 after buying an additional 1,070,900 shares in the last quarter. Finally, ExodusPoint Capital Management LP grew its holdings in shares of Esperion Therapeutics by 221.1% in the fourth quarter. ExodusPoint Capital Management LP now owns 1,171,799 shares of the biopharmaceutical company’s stock valued at $7,300,000 after purchasing an additional 806,848 shares in the last quarter. 85.87% of the stock is currently owned by institutional investors.

Esperion Therapeutics Stock Down 0.7 %

Shares of ESPR stock opened at $1.40 on Friday. The stock has a fifty day moving average of $2.41 and a 200 day moving average of $5.23. Esperion Therapeutics has a 52 week low of $1.12 and a 52 week high of $8.87. The firm has a market capitalization of $107.20 million, a price-to-earnings ratio of -0.39 and a beta of 0.12.

Esperion Therapeutics (NASDAQ:ESPR – Get Rating) last announced its earnings results on Tuesday, February 21st. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.11. The firm had revenue of $18.18 million during the quarter, compared to analysts’ expectations of $20.60 million. The company’s revenue for the quarter was up 18.1% on a year-over-year basis. During the same period in the previous year, the business posted ($1.77) earnings per share. Equities research analysts anticipate that Esperion Therapeutics will post -2.17 earnings per share for the current year.

Esperion Therapeutics Company Profile

(Get Rating)

Esperion Therapeutics, Inc is a pharmaceutical company. It engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets.

Recommended Stories

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.